Catalyst Pharmaceuticals, INC 8-K filings

Catalyst Pharmaceuticals announced that its stockholders have approved the merger agreement with Angelini Pharma, paving the way for the acquisition.

Catalyst Pharmaceuticals announced topline results from a Phase 1 study of vamorolone, indicating on-target glucocorticoid activity without significant immunosuppression at clinical doses.

Angelini Pharma to acquire Catalyst Pharmaceuticals for $4.1 billion in cash, a move that marks Angelini's entry into the U.S. market and strengthens its rare disease and brain health focus.

Catalyst Pharmaceuticals reported record full-year 2025 revenues of $589.0 million, a 19.8% year-over-year increase, and provided 2026 revenue guidance of $615 million to $645 million.

Catalyst Pharmaceuticals increased its full-year 2025 revenue guidance, driven by strong performance in its rare disease portfolio and a robust acquisition strategy.

Catalyst Pharmaceuticals reported strong third-quarter 2025 financial results, with total revenues of $148.4 million, and raised its full-year 2025 total revenue guidance to between $565 million and $585 million.

Catalyst Pharmaceuticals' Board of Directors has approved a new share repurchase program of up to $200 million, leveraging its strong cash position.

Catalyst Pharmaceuticals announced a settlement with Lupin Pharmaceuticals, allowing generic FIRDAPSE market entry no earlier than February 2035.

Catalyst Pharmaceuticals and SERB S.A. have reached a settlement with Lupin, preventing generic FIRDAPSE market entry until February 2035.

Catalyst Pharmaceuticals announced that NCCN Clinical Practice Guidelines for Small Cell Lung Cancer now include new additions for Lambert Eaton myasthenic syndrome, amifampridine, and VGCC antibody tests.

Catalyst Pharmaceuticals, Inc. announced record second quarter and first half 2025 financial results, driven by strong product revenue growth and reaffirmed full-year guidance.

Catalyst Pharmaceuticals, Inc. has expanded its Board of Directors to seven members with the appointment of Dr. Daniel J. Curran, a distinguished pharmaceutical executive.

Catalyst Pharmaceuticals, Inc. announced the retirement of its Chief Medical and Regulatory Officer, Dr. Gary Ingenito, and the immediate appointment of Dr. William Andrews, a seasoned biopharmaceutical executive with extensive rare disease experience, as the new Chief Medical Officer.

Catalyst Pharmaceuticals, Inc. reported the successful election of its Board of Directors and the approval of all proposals at its 2025 Annual Meeting of Stockholders, including an amendment to its stock incentive plan and the ratification of its independent auditor.

Catalyst Pharmaceuticals announces record first quarter 2025 financial results with $141.4 million in total revenue and reaffirms its full-year revenue guidance of $545 million to $565 million.

Catalyst Pharmaceuticals' sub-licensee, Kye Pharmaceuticals, has received priority review from Health Canada for AGAMREE, a potential treatment for Duchenne Muscular Dystrophy (DMD).

Catalyst Pharmaceuticals announces record-breaking 2024 financial results driven by strong commercial performance and the successful launch of AGAMREE, projecting continued revenue growth in 2025.

Charles B. OKeeffe, an independent director of Catalyst Pharmaceuticals, will retire at the 2025 annual meeting after serving on the board since 2004.

Catalyst Pharmaceuticals announces that its sub-licensee, DyDo Pharma, has launched FIRDAPSE tablets in Japan for the treatment of Lambert-Eaton myasthenic syndrome (LEMS).

Catalyst Pharmaceuticals is focused on expanding its orphan drug portfolio through organic growth and strategic acquisitions, aiming to improve the lives of patients with rare diseases.

Catalyst Pharmaceuticals has reached a settlement with Teva Pharmaceuticals, delaying the launch of a generic version of FIRDAPSE until at least February 2035.

Catalyst Pharmaceuticals announced a 25.3% year-over-year increase in total revenue for Q3 2024, driven by strong performance of its rare disease franchise.

Catalyst Pharmaceuticals' sub-licensee, DyDo Pharma, has received approval in Japan to commercialize FIRDAPSE for the treatment of Lambert-Eaton myasthenic syndrome (LEMS), triggering a $2.1 million milestone payment.

Catalyst Pharmaceuticals announced record second-quarter 2024 revenues of $122.7 million, driven by strong performance across its product portfolio and the successful launch of AGAMREE.

Catalyst Pharmaceuticals has granted Kye Pharmaceuticals exclusive rights to commercialize AGAMREE in Canada, a novel corticosteroid for Duchenne Muscular Dystrophy.

The FDA has approved an increase in the maximum daily dose of FIRDAPSE for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) from 80 mg to 100 mg for adults and pediatric patients weighing more than 45 kg.

Catalyst Pharmaceuticals held its 2024 Annual Meeting of Stockholders, electing seven directors and approving an amendment to the 2018 Stock Incentive Plan.

Catalyst Pharmaceuticals announced a 15.4% year-over-year revenue increase in Q1 2024, fueled by strong FIRDAPSE sales and the successful launch of AGAMREE.

Catalyst Pharmaceuticals has announced the U.S. commercial launch of AGAMREE, a novel corticosteroid for the treatment of Duchenne Muscular Dystrophy in patients aged two years and older.

Catalyst Pharmaceuticals announced record full-year 2023 revenues of $398.2 million, an 85.9% increase year-over-year, and is preparing for the commercial launch of AGAMREE in Q1 2024.